OBJECTIVE: Home surveillance monitoring might identify patients at risk for interstage death after stage 1 palliation for hypoplastic left heart syndrome. We sought to identify the effect that a high-risk program might have on interstage mortality and identification of residual/recurrent lesions after neonatal palliative operations. METHODS: Between January 2006 to January 2010, newborns after stage 1 palliation for hypoplastic left heart syndrome or shunt placement were invited to participate in our high-risk program. Patients enrolled in our high-risk program comprise the study group. Patients who had similar operations between January 2002 and December 2005 comprise the control group. Comparisons are made between the 2 groups with respect to interstage mortality and the frequency and timing of interstage admissions requiring medical, catheter, or surgical treatment. RESULTS: Seventy-two patients met the criteria for our high-risk program. Fifty-nine (82%) of 72 patients were enrolled. Among 19 patients with hypoplastic left heart syndrome in our high-risk program, outpatient interstage mortality was zero. Outpatient interstage mortality for the 36 control subjects with hypoplastic left heart syndrome was 6%. Among 40 patients with shunts in the study group, there was 1 outpatient interstage death compared with 4 (6%) deaths in 68 subjects in the control group. Significant residual/recurrent lesions were identified with similar frequency between the 2 groups. However, after shunt operations, these lesions were detected and treated at significantly younger mean ages for patients followed in the high-risk program (P < .005). CONCLUSIONS: Initiation of a high-risk program might decrease interstage mortality after high-risk neonatal palliative operations. Such an approach might contribute to earlier detection of significant residual/recurrent lesions amenable to therapy.
OBJECTIVE: Home surveillance monitoring might identify patients at risk for interstage death after stage 1 palliation for hypoplastic left heart syndrome. We sought to identify the effect that a high-risk program might have on interstage mortality and identification of residual/recurrent lesions after neonatal palliative operations. METHODS: Between January 2006 to January 2010, newborns after stage 1 palliation for hypoplastic left heart syndrome or shunt placement were invited to participate in our high-risk program. Patients enrolled in our high-risk program comprise the study group. Patients who had similar operations between January 2002 and December 2005 comprise the control group. Comparisons are made between the 2 groups with respect to interstage mortality and the frequency and timing of interstage admissions requiring medical, catheter, or surgical treatment. RESULTS: Seventy-two patients met the criteria for our high-risk program. Fifty-nine (82%) of 72 patients were enrolled. Among 19 patients with hypoplastic left heart syndrome in our high-risk program, outpatient interstage mortality was zero. Outpatient interstage mortality for the 36 control subjects with hypoplastic left heart syndrome was 6%. Among 40 patients with shunts in the study group, there was 1 outpatient interstage death compared with 4 (6%) deaths in 68 subjects in the control group. Significant residual/recurrent lesions were identified with similar frequency between the 2 groups. However, after shunt operations, these lesions were detected and treated at significantly younger mean ages for patients followed in the high-risk program (P < .005). CONCLUSIONS: Initiation of a high-risk program might decrease interstage mortality after high-risk neonatal palliative operations. Such an approach might contribute to earlier detection of significant residual/recurrent lesions amenable to therapy.
Authors: Walter Knirsch; Sonia Bertholdt; Gaby Stoffel; Brian Stiasny; Roland Weber; Hitendu Dave; Rene Prêtre; Michael von Rhein; Oliver Kretschmar Journal: Pediatr Cardiol Date: 2014-01-18 Impact factor: 1.655
Authors: Monique M Gardner; Laura Mercer-Rosa; Jennifer Faerber; Michael P DiLorenzo; Katherine E Bates; Alyson Stagg; Shobha S Natarajan; Anita Szwast; Stephanie Fuller; Christopher E Mascio; Desiree Fleck; Deborah L Torowicz; Therese M Giglia; Jonathan J Rome; Chitra Ravishankar Journal: J Am Heart Assoc Date: 2019-05-21 Impact factor: 5.501
Authors: Colette Gramszlo; Allison Karpyn; Jennifer Christofferson; Linda G McWhorter; Abigail C Demianczyk; Stacey L Lihn; Jena Tanem; Sinai Zyblewski; Elizabeth Lucey Boyle; Anne E Kazak; Erica Sood Journal: Cardiol Young Date: 2020-08-06 Impact factor: 1.023
Authors: Sonya Crowe; Deborah A Ridout; Rachel Knowles; Jenifer Tregay; Jo Wray; David J Barron; David Cunningham; Roger C Parslow; Martin Utley; Rodney Franklin; Catherine Bull; Katherine L Brown Journal: J Am Heart Assoc Date: 2016-05-20 Impact factor: 5.501
Authors: Sonya Crowe; Rachel Knowles; Jo Wray; Jenifer Tregay; Deborah A Ridout; Martin Utley; Rodney Franklin; Catherine L Bull; Katherine L Brown Journal: BMJ Open Date: 2016-06-06 Impact factor: 2.692
Authors: Nancy A Rudd; Nancy S Ghanayem; Garick D Hill; Linda M Lambert; Kathleen A Mussatto; Jo Ann Nieves; Sarah Robinson; Girish Shirali; Michelle M Steltzer; Karen Uzark; Nancy A Pike Journal: J Am Heart Assoc Date: 2020-08-11 Impact factor: 5.501